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Sunllnal~ 
Human interleukin 5 (II.-5) plays an important role in proliferation and differentiation of human 
eosinophils. We report the isolation of cDNA clones from cDNA libraries of human eosinophils 
by using murine II.-5 receptor c~ chain cDNA as a probe. Analysis of the predicted amino acid 
sequence indicated that the human IL-5 receptor has 'o70% amino acid sequence homology with 
the murine IL-5 receptor and retains features common to the cytokine receptor superfamily. One 
cDNA  clone encodes a glycoprotein of 420 amino acids (Mr 47,670)  with an NH2-terminal 
hydrophobic region (20 amino acids),  a glycosylated extracellular domain (324  amino adds), 
a transmembrane domain (21 amino acids), and a cytoplasmic domain (55 amino acids). Another 
cDNA encodes only the extracellular domain of this receptor molecule. Other cDNA clones 
encode molecules having diversified cytoplasmic domains. COS7 cells transfected with the eDNA 
expressed a *60-kD protein and bound Ib5 with a single class of affinity (Kd  --  250-590 pM). 
The Ka values were similar to that observed in normal human eosinophils. In contrast to the 
murine 60-kD  oe chain, which binds IL-5 with low affinity (Ka  =  --10 riM),  the human oe 
chain homologue can bind II.,5 with much higher affinity by itself. RNA blot analysis of human 
cells demonstrated two transcripts (*5.3 and 1.4 kb). Both of them were expressed in normal 
human eosinophils and in erythroleukemic cell line TF-1, which responds to IL-5. The human 
IL-5 receptor characterized in this paper is essential for signal transduction, because expression 
of this molecule in murine IL-3-dependent cell line FDC-P1  allowed these cells to proliferate 
in response to IL-5. 
I 
L-5 is a glycoprotein secreted by T  cells and mast cells (1, 
2), originally identified by its ability to stimulate prolifera- 
tion and differentiation in vitro of murine activated B cells 
and CD5 § B cells, and to induce proliferation and differen- 
tiation of eosinophils from bone marrow proliferation (3-9). 
In the human system, IL-5 also promotes proliferation and 
differentiation of eosinophils from bone marrow progenitors 
(10-12). There are contradictory reports, however, describing 
the role of IL-5 on human B cells.  It was reported that it 
induces maturation of human peripheral B cells stimulated 
with Staphylococcus aureus Cowan I into IgM-secreting cells 
(13),  and was also reported to be an IgA-enhancing factor 
(14). However, it was also reported that human Ib5 (hII.,5) 1 
does not show any activity on human B cells in a conven- 
tional B cell assay  (15). 
To clarify the role of IL-5 in the human immune system 
1  Abbreviations used in this paper: FBN III, fibronectin type III; GM-CSF, 
granulocyte/macrophage colony-stimulating  factor; h, human; m, routine; 
ORF, open reading frame;  UTR,  untranslated region. 
and hematopoiesis, we and others attempted to explore the 
characteristics of hlI.-5R (16-19). It was reported that human 
eosinophils in peripheral blood and eosinophilic sublines from 
promyelocytic leukemia (Hb60)  cells express a single class 
of high affinity binding sites for IL-5 with Kas of 170-330 
and 10-50 pM, respectively (16, 18). By cross-linking experi- 
ments, we detected a 55-60-kD protein on normal eosinophils 
(18).  Others reported 60- and 120-130-kD  proteins in eo- 
sinophilic sublines from HL-60 and in an erythroleukemic 
cell line, TF-1  (16,  19). 
We have shown from the series of binding and cross-linking 
studies that murine IL-5 (mlL-5) binds to mlL-SR with both 
high (Ka  =  "~150 pM) and low affinity (Ka  --  "~30 nM) 
and that at least two polypeptide chains comprise the func- 
tional mlbSR (20). We recently isolated cDNA clones en- 
coding the mllc5R ot chain (60 kD)  that binds IL-5 with 
low affinity (21). It is very suggestive that there is a significant 
homology between h- and mlL-SRs, because mlL-5 was shown 
to bind hlI~SR as efficiently as hlL-5, and they are ',~70% 
homologous in terms of amino acid sequences (13, 14). Then, 
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hybridization using  mlL-5R c~ chain cDNA  as  a probe. 
In this report, we describe the characterization of hlL-5R 
by isolating the cDNA clones for it.  rhlL-5R expressed on 
COS7 cells showed similar binding properties and biochem- 
ical characteristics to those of the native receptor on human 
eosinophils. Analysis of the sequence of hlL-SK demonstrates 
that the hlL-5R is also a member of a cytokine receptor su- 
perfamily and contains three fibronectin type III (FBN III) 
modules  (22-26). 
Materials and Methods 
Reagents and Cell Lines.  rmlL-5  and  3SS-methionine labeled 
mlL-5 were prepared according to procedures described previously 
(27). rhlL-5 was purified using anti-IL-5 mAb NC17 (28) from the 
culture supernatant of Spodoptera frugiperda (Sf21) cells transfected 
with hlL-5 cDNA in baculovirus expression vector (unpublished 
results),  rhlL-5 was labeled with l~SI using diiode-Bolton-Hunter 
reagent (4,000 Ci/mmol; DuPont-New England Nuclear, Boston, 
MA) as described (29). rhlL-2 was a kind gift from Takeda Central 
Research Institute (Osaka, Japan). rhlb3, rhlb4, rhlL-6,  recom- 
binant human granulocyte colony-stimulating factor (G-CSF),  and 
human recombinant granulocyte/macrophage colony-stimulating 
factor  (GM-CSF)  were  from Japan  Roche  Research  Institute 
(Kamakura, Japan), Ono Pharmaceutical  Co., Ltd. (Osaka, Japan), 
Dr. T. Hirano (Osaka University, Osaka, Japan), Chugai Pharmaceu- 
tical Co., Ltd. (Tokyo, Japan), and Sandoz Pharmaceutical Co., Ltd. 
(Basel, Switzerland), respectively. Human erythroleukemic cell line 
TF-1 (30) was a generous gift from Dr. T. Kitamura (DNAX Re- 
search Institute of Molecular and Cellular Biology, Palo Alto, CA). 
Human eosinophilic leukemia cell line Eob3 and human adult T 
cell leukemia cell line ATL-2 were kindly provided from Drs. M. 
Hirashima and N. Asou (Kumamoto University Medical School, 
Kumamoto, Japan), respectively. All human cell lines were main- 
tained in RPMI 1640 containing 10% FCS, 5  x  10 -5 M 2-ME, 
100  U/ml  penicillin,  and  100  #g/ml  streptomycin.  A  mlL-3- 
dependent cell line, FDC-P1, was maintained in the same medium 
in the presence  of 10 U/ml of mlL-3. 
RNA Isolation and Construction of cDNA Library.  Human eo- 
sinophils were isolated from peripheral blood of healthy volunteers 
or from a patient with idiopathic eosinophilic syndrome. In brief, 
eosinophils  were purified from the 0.5%  polyvinylpyrrolidone- 
sedimented  erythrocyte/leukocyte fraction  of peripheral  blood 
through discontinuous layers (density, 1.080-1.100) of Percoll (Phar- 
macia LKB Biotechnology, Uppsala, Sweden) as described (18). Total 
RNAs were prepared from eosinophils by the guanidium isothio- 
cyanate/CsTFA method (31), and poly(A) + RNA was selected by 
oligo(dT)-cellulose column chromatography, cDNA library from 
eosinophils  from healthy volunteers was constructed in the vector 
with  chicken ~-actin promoter,  pAGS-3  (32).  Double-stranded 
cDNA was  synthesized using random primer according to the 
method by Gubler and Hoffman (33)  using  5 /xg of poly(A) § 
RNA with the manufacturer's kit (Bethesda  Research  Laborato- 
ries,  Bethesda,  MD).  The blunt-end cDNA was  modified with 
BstXI linkers,  size fractionated by 5-20% potassium acetate gra- 
dient centrifugation, and cDNA '~>1.0 kb was cloned into pAGS-3 
as described (34). Transformation ofEscherichia coli strain MC1061 
was carried out by electroporation (2.5 kV, 25/~F, 200 f]) in 0.2- 
cm cuvettes using Gene Pulser apparatus  (Bio-Rad Laboratories, 
Richmond,  CA)  (35).  Approximately 106 independent colonies 
were obtained by transforming MC1061  with pAGS-3 cDNA li- 
brary, cDNA library from a patient with eosinophilia  was con- 
structed in the kgtl0 vector using 5 #g of poly(A) + RNA.  1.6 
x  106 independent plaques  were obtained. 
Screening ofcDNA Libraries.  Screening of the pAGS-3 library 
was performed using a 32p-labeled 1.2-kb  HindllI-PstI fragment 
of mll.,5R cr chain cDNA clone plL-SR.8 (21) as a hybridization 
probe under low-stringency conditions. Colonies were blotted on 
nitrocellulose membranes (Millipore,  Bedford, MA) and hybrid- 
ization was performed at 65~  with 10x  Denhart's solution, 6 x 
SSC, 0.5% SDS, 100 #g/ml of denatured salmon sperm DNA for 
20 h, and washed with lx  SSC, 0.1% SDS at 45~  (36). Subse- 
quently, a 1.0-kb  XhoI fragment of positive clone (phSR.1,  see 
Results) was used as a probe to isolate other clones from the hgtl0 
library.  Plaques  were transferred to nylon membranes (Colony/ 
Plaque Screen; DuPont-New England Nuclear) and hybridization 
was performed according to the manufacturer's recommendation 
and washed with 2x  SSC,  1% SDS at 65~  All hybridization 
probes were labeled with a-[3~p]dCTP  by random primer labeling 
method using a kit from Pharmacia LKB Biotechnology. 
DNA  Sequencing.  The  cDNA  inserts  of  clones,  ph5R.1, 
hhSR.12, kh5R.27, and kh5R.25, were sequenced by the dideoxy 
chain termination method (37) using the modified T7 polymerase 
(Sequenase; U.S. Biochemical  Corp., Cleveland,  OH) after being 
subcloned into pBluescript KS(-) vector (Stratagene, La Jolla, CA). 
Expression of the hlL5R cDNA.  A transient expression system 
with COS7 cells was used together with the mammalian expres- 
sion vector pCAGGS (38) (generously provided by Dr. J.-I. Miya- 
zaki, University of Tokyo, Tokyo, Japan), which is a derivative of 
pAGS-3 (32). An EcoRI fragment of either kh5R.12 or Xh5R.27 
clones was inserted into a unique EcoKI site of pCAGGS, resulting 
in pCAGGS-hSK.12 or pCAGGS-h5R.27. Each plasmid DNA was 
transfected into COS7 cells by electroporation as described  (39). 
COS7 transfectants were cultured in DME containing 10% FCS, 
100 U/ml penicillin,  and 100 #g/ml streptomycin. After a 3-d cul- 
ture, cells were harvested with the treatment of PBS containing 
0.5 mM EDTA and subjected  to further analysis. 
For FDC-P1 cells, pSV2-neo and pCAGGS-5R.12 (1 and 20/~g, 
respectively)  were cotransfected by electroporation at 1.5 kV and 
25/zF. Stable transfectants were selected with 400 #g/ml of G418 
(geneticin; Sigma Chemical Co., St. Louis,  MO). 
Binding Assay and Scatchard Analysis.  For competition experi- 
ments, COS7 transfectants were harvested and suspended  at 4  x 
105 cells per 100 #1 of the binding medium (RPMI 1640, 25 mM 
Hepes, pH 7.2, 0.1% BSA), and incubated with 500 pM nSI-hlL-5 
(2.0  ￿  1013 cpm/mmol)  in  the presence  of >1,000-fold molar 
excess of unlabeled various cytokines at 4~  for 1 h (18, 29). For 
binding assay, COS7 transfectants were resuspended at 5-10  x  104 
per 100 #1 of the binding medium, and incubated with increasing 
concentrations  of 12SI-hlL-5 or  3sS-labeled mlL-5  (2.3  x  1015 
cpm/mmol) at 4~  for 1 h. Specific binding was defined as the 
difference between total binding and nonspecific binding obtained 
in the presence of a 250-fold molar excess of unlabeled IL-5. The 
Kd was calculated  by Scatchard  plot analysis (40) of the binding 
data. 
Chemical Cross-linking.  COS7 transfectants were cultured for 
3 d and resuspended at 2.5  x  106 cells in I ml of binding medium. 
Cells were incubated with either 5.5  nM 35S-labeled mlL-5 or 1 
nM l~SI-hllr  at 4~  for 1 h in the absence or presence of a 250- 
fold molar excess of unlabeled IL-5 and subsequently cross-linked 
with 1 mM BS  3 (Bis[sulfosuccinimidyl]  suberate)  (Pierce Chem- 
ical Co., Rockford, IL) at 4~  for 30 min (16). Cells were then 
washed and lysed with lysis buffer containing 1% Triton X-100 
in the presence of protease inhibitors (2 mM EGTA, 2 mM EDTA, 
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O-phenanthroline, and aprotinin at 200 KIU/ml) as described (29). 
The detergent extraction mixture was subjected to SDS-PAGE with 
7.5% polyacrylamide  under nonreducing conditions, and then ana- 
lyzed by a Bio-Analyzer  (model 100; fuji Photo Film, Tokyo,  Japan). 
RNA  Blot Analysis.  Poly(A)  + RNA  (6 /~g) prepared from 
human eosinophils in peripheral blood, TF-1, EoL-3, ATL-2, Raft, 
and U-937 were subjected to electrophoresis through 1% agarose 
gel containing 2.2 M formaldehyde as described (36), and trans- 
ferred to a nylon membrane (Gene Screen; DuPont-New England 
Nuclear). Hybridization was carried out according  to manufacturer's 
recommendation using a 32p-labeled full-length EcoRI cDNA in- 
sert of ~hSR.12 as a probe. 
Proliferation Assay.  FDC-P1  cells and FDC-P1 transfectants  were 
inoculated  in  a  96-well microtiter  plate  at a concentration  of 
104/0.2 ml/well with various concentrations of hlL-5. They were 
pulse labeled with [3H]thymidine (0.2 #Ci per well) during the 
last 6 h of a 48-h culture period, and incorporated [3H]thymidine 
was measured by a liquid scintillation counter. 
Results 
Isolation and Characterization of hlL 5R cDNA Clones.  Two 
cDNA libraries of human eosinophils prepared from normal 
volunteers and from a patient with eosinophilia were used 
to isolate hlL-5R cDNA clones. At first, screening was per- 
formed by cross-species hybridization using mlL-5R a  chain 
cDNA clone as a probe at low-stringent conditions. One clone, 
ph5R.1, that has a 931-bp insert was obtained from pAGS-3 
library of normal human eosinophils (Fig.  1 A). This clone 
did not cover the entire coding region of hlL-5R. Then, three 
clones (~5R.12, khSR.27, and h,  hSR.25) were isolated from 
~gtl0 library of eosinophils from an eosinophilia patient using 
ph5R.1  as a probe by plaque hybridization, cDNA inserts 
from ~5hR.12,  h.hSR.27,  and ~h5R.25  were found to be 
2,006,  2,024,  and  1,405  bp,  respectively (Fig.  1 A).  Both 
~hSR.12 and ~,hSR.27 have the open reading frame (ORF) 
that encodes a protein equivalent to mlL-5R o~ chain in mo- 
lecular size. Because the nudeotide sequence of the ORF of 
MaSR.12 clone (1,260 bp) was the best match for the mlL-5R 
a  chain (21) in terms of constitution,  this clone was ana- 
lyzed most in this paper. The nucleotide sequence of hlL-SR 
from Xh5R.12 is shown in Fig. 1 B. A 3' untranslated region 
(3' UTR) of 685 nucleotides extends without the polyade- 
nylation signal AATAAA. The ORF of khSR.12 encodes 
a mature protein of 400 amino acids with a calculated molec- 
ular weight of 45,556 synthesized with a 20-amino acid signal 
sequence. The site of signal sequence was in agreement with 
the sites based on the predictive system of yon Heijne (41). 
The mature hlL-5R protein of 400 amino acids can be divided 
into several regions according to a prediction by the Doo- 
little hydropathy plot (42); the extracellular domain was com- 
prised  of 324  amino  acids,  transmembrane  domain  was 
comprised of 21 amino acids, and cytoplasmic domain was 
comprised of 55 amino acids. The extracellular domain con- 
tains two pairs of cysteines and a "WSxWS" box,  as seen 
in  a  cytokine receptor superfamily (22-24).  Six  N-linked 
glycosylation sites  were seen. 
There was a 57-bp insert in the cytoplasmic domain of 
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the phSR.1 clone, generating a 19-amino acid insertion in 
this domain (Fig. 1 C). The 3' UTR ofph5R.1 has 511 nucleo- 
tides, which is the same as the 3' UTR of ~h5R.12, except 
for one base:  the 1,714th  T  in Xh5R.12 is changed into C 
in ph51k.1. 
The nucleotide sequence of the ~h5R.27 clone was iden- 
tical to that of ~h5R.12 in extracellular domain and trans- 
membrane domain, except a point mutation at position 385 
that  changed G  to A  resulting in a change of Val to  lie. 
~h5R.27 was distinguished from Xh5R.12 by having a to- 
tally different sequence of 737 bp, which starts from nucleo- 
tide 1185 (Fig.  1 D). Consequently, the cytoplasmic domain 
of ~hSR.27 is 24 amino acids shorter than that of ~h5R.12. 
hah5R.25 clone encodes an hlL-SR that has neither a trans- 
membrane domain nor a cytoplasmic domain. The site indi- 
cated by the open arrowhead (Fig. 1, A and B) is the predicted 
site of splicing that is followed by an unique sequence resulting 
in the addition of two amino acids before termination (Fig. 
1 E). This predicted site of splicing is very similar to that 
observed in pIL.5R.2 encoding soluble mlL-SR (21). The se- 
quence upstream  from  this  arrow  is  identical  to  that  of 
XhSR.27.  Thus,  ~kh5R.25 may code for a soluble form of 
hlL-5R.  This predicted mature protein is 313  amino acids 
in length with a calculated Mr of 35,607. 
Three Units of  a FBN III Module in the Extracellular Domain 
and  the  Proline Cluster  Region  in  the  Cytoplasmic  Domain. 
Alignment of the predicted amino acid sequence of the hlL- 
5R (~kh5R.12) with that of the mlL-SR c~ chain (21) exhibited 
a high degree of homology (69%  homology) throughout 
the length of the molecules (Fig.  2).  In addition, all seven 
of the extracellular and four of the transmembrane and intra- 
cellular cysteine residues are conserved in the h- and mlb5R 
molecules. Four of the six potential N-glycosylation sites are 
conserved in the mlL-SR oL chain (Asn35, Asn131, Ash216, 
and Ash244) (data not shown). A part of the extracellular 
domain of hlL-5R (126-344  amino acid residues) contains 
two pairs of cysteine residues and the "WSxWS" box (Fig. 
2 A). The hlI:5R, therefore, belongs to a cytokine receptor 
superfamily (22-24), as in the mlL-5R o~ chain (21). We ex- 
amined the extraceUular domain in view of sequence and struc- 
tural pattern matching as others did (25, 26, 43-46). We de- 
tected FBN III motifs not only in domains that belong to 
the cytokine receptor  superfamily, but  also  in  the  NH2- 
terminal domain (21-125  amino acid residues) (Fig.  2 A). 
There were conserved motifs such as a pair ofproline residues 
that precede an amphiphilic/8 strand and a conserved trypto- 
phan. In the cytoplasmic domain, the proline cluster region 
(21) (from Leu371 to Asp384) is well conserved in the h- and 
mlL-5R molecules (Fig.  2 B). 
Binding and Biochemical Characteristic of hll_,5Rs.  We ex- 
amined the binding specificity of the protein coded by the 
cDNA clones, by expressing the cDNA in COS7 cells. We 
inserted Xh5R.12 and XhSR.27 cDNA fragments into the 
expression wctor pCAGGS (38), resulting in pCAGGS-h5R.12 
and pCAGGS-hSR.27, respectively.  These two recombinant 
clones were transfected into COS7 cells. The binding of 2251- 
hlL-5 to the COS7 cells transfected with pCAGGS-h5R.12 
was specific for IL-5. Other human cytokines such as IL-2, A 
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GTCTTTTGAAAGGAT•TGCCG•TCCTTC•CATCGCATGGCCAc•CCA•TTCTcAGGCCAGCCA•A•TGAGCAT•GGTCC• 
G  TCCCTGAC GCTAT  ~  G  ￿9  GC  TA  GA  I"CC  TGGGG  T  TGCAGC  CA  C ~AC~:AT~GACAC~ACAGACAUGGTCCTC~CCATCTTCTGTTGAGTACTG~TCGGAACAAGAGGATCGTCTGTAGACAGGAT 
ATG  ATe  ATC  GTG  CCG  CAT  GTA  TTA CTC  ATC  CTT TTG C,C,G  GCC ACT GAG ATA CTG  CAA C~T  GAC  TTA  CTT CCT GAT  GAA  AAG  ATT  TCA CTT 
Met  Ile  Ile  Val  Ala  His  Val  LeU  Leu  lle  Leu  Ueu  GI~  Ala Thr  GIu  lle  Leu Gln  Ala  Asp  Leu  Leu  Pro  Asp GIu  Lys  lle  Ser  L~U 
crc CCA CCT GTC AAT  TTC  ACC ATT 
Leu  Pro  Pro  Val  Ash  Phe  rhr  lie 
GTT  AAT  CTA  GAA  TAT  CAA GTG  AAA 
Val  AS  sn  Leu  Glu  Tyr  GID  Val  Uys 
HIS  LyS  GIy  Phe  Ala  Set vai 
CCA  CCA GGG  TCT  CCT  GGA  ACC  TCA 
Pro  Pro G1y  Ser  Pro  GIF  Thr  Ser 
GTT  TCC CTT  CAC  TGC ACC  TGG CTT 
Val  get  Leu  }{~s Cy5  Thr  Trp  l,eu 
GAA  TCC CAA  GAA  TAC  AGC AAA  GHC 
GIu  Cys  Gin  GIu  Tyr  Set  Lys  ASp 
CTT  CCG  GTG  CTT GTT  AAC GGC  TCC 
Leu  Ala  Val  Leu  Val  Asn GI~  Ser 
CCT  CCA  CTG  AAT  GTC  ACA  C~CA GAG 
Pro  Pro  Leu  ASh  Val  Thr Ala  GIu 
GAT  TAT GAA  GTA AAA  ATA  CAC  AAT 
Asp Tyr Giu Val  Lys  Ii~  His  AS~ 
CTT  TCT AAG  TAC GAT  GTT  CAA  GTG 
Leu  Set  Lys  Tyr Asp  Val  Gin  Val 
O 
GTG  GGA AAT  GAT  GAA  CAC AAG  CCC 
Val  Gly Ash  Asp  GIu  His LyS  Pro 
ATC  TGT  AAAATA  TGT  CAT  TTA  TGG 
Tyr  Glu  Lys  Ala Gly  Ser  Set GIu 
AAA  GTT  ACT  GGT  TTG  GCT  CAA  GTT 
LyS  Val  Thr  Gly  Leu  Ala  Gin  Val 
ATA  ~c  CCT  CCA  AAA  GAA  GAT  GAC 
lle  Ash  Ala  Pro  Lys  Glu  Asp  Asp 
CGG  ACC ATC  CTG CAG  AAC  GAC  CAC 
Acq Thr  lle  Leu  Gin  Asn Asp  His 
GTT  GTG AAT  TTA ACT  TGC ACC  ACA 
Va[  Va[  ASh  Leu  Thr Cys  Thr  Thr 
GTT  GGC ACA  GAT  GCC  CCT  GAG GAC 
Val  Gly  Thr  Asp  Ala  Pro Glu  Asp 
ACA  CTG C=C~ AGA  hAT  ATC GCA  TGC 
Yhr  Leu  Gly  Arg Ash  lie  Ala  Cys 
AC,  C  AAG CAC TCT C~CT ATC  AGG  CCC 
So: Lys  His  Set Ala  lle Arq  Pro 
ATT  GAAGGA  ACT  CGT  CTC  TCT  ATC 
lle  Giu GIy  Thr Arq  Leu  Ser  lle 
ACA  AGG AAT  GGA  TAT  TTG CAG  ATA 
Thr  Arq ASh  Gly  Tyr  Leu  Gin  IIQ 
AGA  GCA GCA  GTG ACC  TCC  ATG  TGC 
Arg  Ala  Ala  Vai  Ser  Ser Met  Cys 
TTG  AGA  GAG  TGG  TTT  GTC ATT  GTG 
Leu  Arq  Glu  Trp  Phe  Val [Ile  Val 
ATC  AAG  TTG  TTT CCA  CCA ATT  CCA 
lie  Lys  Leu  Phe  Pro  pro  Ile  Pro 
ACG  GAA  ATT G~  GTC  ATC TGT  TAT 
Thr  Clu  I1o  Glu Val  lie Cys  Tyr 
CTT  TTA CAA  TGG AAA  CCA  AAT  CCT  GAT CAA  GAG  CAA  AGG  AAT 
Leu Leu  Gin  Trp  Lys  Pro Ash  Pro  Asp  Gln  GIu  Gln  Arq Ash 
TAT  GAAACC  AGA  ATC ACT  GAAACC  AAA  TGT  GTA  ACC  ATC CTC 
Tyr Glu  Thr  Arg  lle  Thr  GIu  Ser  Lys  Cys  Val  Thr  lle  L~U 
TCA CTA  CTG GCC  AGC  AGC  TGG  GCT  TCT CCT  GAA  CTT  CAT  GCC 
Ser  Leu  Leu  Aia  Sor  Ser  T~pAla  Set Ala  Glu  Leu  His  Ala 
AAC  ACT  ACA GAA  GAC  AAT  TAT  TCA  CGT  TTA  ACaG TCA  TAC CAA 
ASN  Thr  Thr GIU  Asp~  Arq  Leu  Arg  Set  Tyr Gin 
ACG CAG  TAT  TTT CTC  TAC  TAT  AGG  TAT C4~C TCT  TC~ ACT  GAA 
Thr Gin  Tyr  Phe Leu  Tyr  Tyr Arq  Tyr Gly  Set  TIp  /hr  GIU 
TGG rrr CCC AGG  ACT  TTT ATC  CTC  AGC  A~  CC~ CGT  GAC  TGG 
Trp  Phe Pro Arq  Thr  Phe  Ile  Leu  Ser  Lys  Gly  Arg  Asp  TZ]) 
TTT  GAT  CAG CTG  TTT GCC  CTT  CAC CCC ATT  GAT  CAA  ATA AAT 
Phe Asp  Olm  L~U  Phe Ala  Ueu  His  Ala  Ile  Asp  Gln  lie Ash 
CAA  TGG  GAG AAA  CCA GTG  TCT CCT  TTT  CCA  ATC  CAT  TGC  TTT 
Glm  Trp  Giu  Lys  Pro Val  Set Ala  Ph.  Pro  Ile  His  Cy.  Phe 
GAA AAA  TTG ATG  ACC  AAT  CCA  TTC  ATC  TCA  ATA  ATT  GAT  GAT 
GIu  Lys  L.U  MA~t Thr Asm  Ala  PhQ  IIQ  Ser  Ile  Ile  Asp Asp 
AGA  GAG  C~A  GGG  CTC  TGG AGT  GAG  TC~3  AGC CAA CCT ATT  TAT 
Arq  Giu  Ala  Gly  Lou  Trp  Ser GIu  Trp  Ser Gln  Pro  Ile  Tyr 
ATT ATGGCA  ACC ATC TGC  TTCATC  TTG  TTA  ATT  CTC  TCG CTT 
Ile  Met  Aia  Thr  lle  Cys  Phe  lle  Leu  Leu  lle  Leu  Set Leu 
CCA CCA  AAA  AGT  AAT ATC  AAA CAT  CTC  TTT  GTA ACC  ACT  AAC 
Ala  Pre  Lys  Set  ASS  lls  Lys  Asp Leu Phe Val  Thr Thr Ass 
ATA GAG  AAG CCT GGA GTT  GAG ACC  CTG GAG GAT  TCT  GTG  TTT 
lie GID  Lys  ~ro  Gly Val  Glu  Thr  Leu  GIu  Asp  S.r  Val  PhQ 
TGA  •TGT•ACTTTC••/CA•C•TCTGATGAAcTCA•A•ATGCCTCAG•CCCTCAGTGAAAAGAACACCGATCCTGC4S••TTGGCTAAGAGG•GTTCAGAATTTAGGCAACACTCAATTTA 
C  C  T  GC  G  AAG  C  AA  T  ACA  CC  C  AGACAC  A  C  CAG  T  C  T  T  G  T  A  T  C  T  C  T  T  AAAA  G  T  A  T  G  G  A  T  CC  T  T  C  A  T  CCAAA  T  C  C~C  T  CA  C  C  T  A  CAGCAGG  G  AAG  T  T  GAC  T  CA  T  C  CAA  CCA  T  T  T  T  CC  CA  T  G  T  T  T 
T  T  T  C  T  C  C  CC  A  T  GCCG  T  AC  A  C'C￿G T  A  GC  A  CC  T  CC  T  C  A  C  C  T  GCCAA  T  C  T  T  T  CCAA  T  T  T  CC  T  T  G  A  C  T  C  A  C  C  T  C  A  GAC  T  T  T  T  C  A  T  T  CAC  AA  C  AGACACC  T  T  T  T  AAGCC  T  AAC  G  T  CCA  GC  T  G  T  A  T 
TTACTTCTGGCTGTCCCCGTTTGGCTGTTTAAC~GCCAATTGTAGCACTCAGCTACCATCTGAGGAAGAAAGCATT~TGCATCAGCCTCGAGTGAATCATGAACTTGGATTCAAGACT 
G  T  C  T  T  T  T  C  T  A  T  A  GCAAGT  GAGA  CCCACAAA  T  T  CC  T  CA  C  C  CCCC  T  ACA  T  T  C  T  A  G  AA  T  GA  T  C  T  T  T  T  T  C  TAG  G  T  AGA  T  T  G  T  G  ?A  T  G  T  G  T  G  T  G  T  A  T  GAG  A  GAGA  GAG  A  GAGAGAGA  G  AGAGAG 
AGAGAGAGAAATTATCTCAAGCTCCAGACGCCTGATCCAGGATACATCA•TTGAAACCAACTAATT•AAAAGCATAATAGACCTAATATAT 
GTC  CTC  TCC ATT  TTC ATA  TAC ATC  TTA GAT  TCG  GCT GAC  AAT  TTT  CTA CAA  AAA AAG 
Val  Leu  Cys  Ile  Phe  lle  Tyr  lle  Leu  Asp  Ser  Ala  Asp  ASh  Phe  Leu  Gln  Lys  LyS 
A  ATT  TAA  A•TCAAGCATGTTTTAACTTTTGG•TTAAGGTAC•TGGGTGTACCTGGCAGTGTTGTAAGCTCTTTACATTAATTAATTAACTCT•TAGGTA•TGTTATC•TCATTT 
Gly  lle  --- 
TATAAACAACGCAGCTGAAGTTGAGAGAAAT•AGTAACCTGTCCTAGGTCACACAATTAGGAAATGACAGATCTGC/•AGTCTATTTCCAGGCAGTCTATTTCCACGAGGTCATGAGTGC 
~AAAGAGGGACTAGGGGAAGAATGA~TAACTCCAGGGAGCTGACTTTTCTAGTGTGCTTACCTGTTTTCCATCTCTCAAGGAT~TGCCATGAA~CTGTACCCAGGT~TTGTHCCAC 
AGCCCTGACATGAACACCTGATGGCACCTCCTGGGTTGGAGCCTAGACAA~AACATGAAGAACCATGCCTCCTGCCTGAGCCCATC~TGCTGTAATTATAGAAAACCT~T~G 
AATATGCTGATATTTTTCAGA~AAGTACCCCTTTTATAAAAATCCTCCAAGTTAGCCCTCGATTTTCCATGTAAGGAAACAGAGGCTTTGAGATAA~GTCTGTCTCCTAAGC~ACAAAG 
CCAGGACTTGATCCTGTCTTAAAAATGCAAAATGTAGTACTTCTTCCATCAAACGTAGACATGC~C~AAGGGACAGGTTTTGGCTTC~`1TATCAGAATACATTTTTAAAAGC~GTGTAAG 
AA  T  TGA  ACGGGC  TG  T  AC  TA  GGGGG  T  A  TA 
GTAAG  TAG CTTATGT•TATTTTA•ATTGG•AGC•TTCCTT•TGAT•AAAAAAGGTAATC••AGAAACGTAC•CGTTCACTCGTGGGTCTTAAAATGGTTTCATATCTCTATTGTG 
Gly  Lys  - 
ACTAATTTTCTCTCGGTCTACTCCCTTTTCAATCAGGAATAGATTTGCCATGAACCCAGTGAAGTTTTTAA•TGTCTAGGC••CTCATTAGCGCCAC 
Figure 1.  Structure of the hlI:5R 
cDNAs. (A) Schematic representa- 
tion and restriction maps of hlI~SR 
cDNAs.  The  coding  regions  are 
boxed. The hatched boxes represent 
the signal sequence; solid boxes rep- 
resent the transmembrane domain. 
The open triangle indicates regions 
where there is an insertion  in the 
cytoplasmic  domain  of  ph5R.1, 
taking the structure of Xh5K.12 as 
a standard. The thinner  open box 
at the 3' end of hhSR.27 represents 
a  different  nucleotide  sequence 
from that of kh5R.12. The striped 
thinner box in hbSR.25 indicates a 
unique 3' UTR among four clones. 
The filled  diamond and the plain 
arrow represent the 5' terminal of 
hh5K.12 and hh5R.27, respectively. 
(B)  The  nucleotide  sequence  and 
deduced amino acid sequence of the 
hlL-5R cDNA. Nucleotides and de- 
duced amino acids are numbered on 
the left. The nucleotide sequence of 
5' UTR is from MaSR.25. hh5R.27 
and khSK.12  start from the thin 
arrow and the filled diamond, re- 
spectively.  The first underlined  20 
amino acid residues  represent the 
signal  sequence.  The  transmem- 
brahe domain is marked by a filled 
box. The potential N-linked glyco- 
sylation  sites are shown by double 
underlines.  Cysteine  residues are 
marked by asterisks.  (C) The nu- 
cleotide  sequence  and  deduced 
amino acid sequence  of the inser- 
tion present  in ph5R.1.  Insertion 
occurs after nudeotide 1176, desig- 
nated by the open triangle in A and 
B. (19) The nucleotide sequence and 
deduced  amino  acid  sequence  in 
kh5R.27,  which  occur  after the 
filled triangle in A  and B. (E) The 
nucleotide  sequence  and  deduced 
amino acid sequence in Xh5R.25, 
which occur after the open arrow in 
A  and B. These sequence data are 
available  from  EMBL/GenBank/ 
DDBJ  under  accession  numbers 
X61176  (clone  Ma5R..12), X61177 
(clone  kh5R..27),  X61178  (clone 
ph5R.1),  and  X62156  (clone 
kh5R.25). 
Ib3, I1.-4, IL-6, G-CSF, and GM-CSF did not compete with 
ILo5, as shown in Fig.  3.  The results of binding assays for 
t2SI-hlL-5 to these COS7 transfectants are shown in Fig. 4, 
A  and B. Transfectants  with pCAGGS-hSK.12 or pCAGGS- 
h5R.27 expressed a single affinity class of IL-SR with an ap- 
parent Kd of 590 and 410 pM,  respectively.  Because of the 
low specific  radioactivity of this ligand, we could not mea- 
sure the specific binding under ,,o100 pM.  Since we found 
that the 3sS-labeled  mlI~5 binds to human eosinophils and 
this binding can compete with either cold raiL-5  or hlL-5 
in  a  similar  manner  (18)  and 3sS-labeled  mlL-5  had much 
higher specific  radioactivity, we applied asS-labeled mlL-5 in 
this binding assay. The binding assays for 3sS-labeled  raiL-5 
to the COS7 transfectants with these cDNA clones are shown 
in Fig. 4, C and D. Transfectants  with pCAGGS-h5R.12 or 
pCAGGS-h5R.27  expressed a single affinity class of IL-5R 
with an apparent Ka of 355 and 250 pM, respectively.  These 
Kd values are quite  similar to those of normal human eo- 
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,  hlL5R  29  SLL~TI-~I"I  *~i 
mlL5R  123  GT  SV~T~T~VVS  S  H  T  HLRP  Y  Q~  R~q 
Q  I  N~NVTAE IE ....  LSI(  ~]  hIL5R 238 
mILSR 235 QVN  N~IE  ............ SgYI[ 
####P##L##T##T ....  #TS##V#W#P  P###  ITGYR####P# ......  ###########P##--##S#T#  #GL#PG#EY#V#VYAV##  ........  ##ES# P######T 
EQRNVNL[  V]K  I  NAP  KEDDYETRI TESKC~ ILHK-  -G[~ASV'RT  ~-~NDH  SLL~S~AELHAPPGSP 
FLYYRFG  V"LTEKC_QEYSRDALNRNTACWFP  RTF  I  NSKGFEQLAVH  I  NGSSKRA-  -  - AIKPFDQLFSPLAI  O 
s  HNTRN  .......  GYLQ  I  EKLMT  ......  NAF  I  S  I  I  DDLS~VSSMCREAGLWSE~P  I  YVGNDEHK 
,LKIYNTKN  ......  GHIQKEKLIA  ....  NKFISKIDDVS6I~  ~VSSPCR~GRWGE  PIYVGK ERK 
B  hlL5R 366  HLW  I  ~FP  P  I  PAP  KSN  IK~FVTTNYEKAGS SET5  IEVl  C  Y  I  EKPG~TLEDSW 
mlL5R  362  HLWT  FPPVPAPKSNIK  PVVTEYEKp  -S  NETK  IEWHCVEEVGFEV~GNSTF 
Figure  2.  Alignment of human and murine ID5R amino acid sequence.  (.4) Alignment of human and murine IbSR extracellular region  with a 
consensus  sequence  of a FBN III module. The consensus  sequence  of FBN III was distilled by Hibi et al.  (46).  Nonconserved amino acid residues 
and gaps are indicated by # and  -,  respectively. The residues identical with those of the FBN III module are boxed.  Four conserved cysteine residues 
and "WSxWS" box, commonly seen in the cytokine receptor superfamily  (22-24),  are indicated  by thick bars. (B) Comparison of the amino acid 
sequences from the cytoplasmic domain of IL-5R between human and mouse. The conserved proline cluster region is boxed. Numbers at the left indicate 
the amino acid number starting from the first methionine. Identical and related amino acids between the hlL-5R and mlb5R a  chain (21) are shown 
by asterisks and dots,  respectively. 
sinophils, which we reported in our previous paper (Ka  = 
170-330 pM) (18). 
The molecular mass of the hlb5R on transfected COS7 
cells was estimated by chemical cross-linking  experiments. 
When  asS-labeled mlL-5 was cross-linked with the COS7 
cells  transfected with pCAGGS-h5R.12,  a single  band of 
"~100 kD was observed. After subtraction of the molecular 
mass of asS-labeled raiL-5 ('~45 kD),  estimated molecular 
mass of hlI:5R was '~55-60 kD (Fig. 5 A). In the case of 
the cross-linking experiment with 12SI-hlL-5, whose molec- 
ular mass is "~30 kD, the molecular mass of the major band 
was '~85 kD. The expected molecular mass was ~55-60 kD, 
as shown in Fig. 5 B. The molecular weight of the mature 
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Figure  3.  Specificity  of 12SI-hlL-5 binding  to  rhlL-5R  expressed  in 
COS7 cells transfected with pCAGGS-h5R.12. Radioligands  were added 
at 500 pM, and the competitors  were at >1,000-fold molar excess. The 
bars represent the SD of three experiments. 
hlL-5R calculated from the predicted amino acid sequence 
is 45,556,  and it is likely that the higher molecular weight 
observed for the expressed receptor molecule is due to glycosy- 
lation or other posttranslational modifications. The estimated 
molecular weight of hIL-51L derived from the cDNA cloned 
in this study was very similar to that of hIL-5R of normal 
eosinophils  in human peripheral blood (18). 
Expression of the hlL5R Transcripts.  Expression  of the hlL- 
5R mRNA was examined by Northern hybridization with 
a cDNA insert from kh5R.12 as a probe. RNA blot analysis 
of human cells demonstrated the presence of two mRNA 
transcripts of ",6.3 and "~1.4 kb in normal eosinophils and 
human erythroleukemic cell line TF-1 (Fig.  6,  lanes I  and 
2). These bands were absent in the RNA prepared from eo- 
sinophilic leukemia EoI,3, adult T cell leukemia ATb2, Bur- 
kitt lymphoma cell line Raft, and histiocytic lymphoma cell 
line U-937 (Fig. 6, lanes 3-6). In general, this pattern of ex- 
pression of hlL-5R mRNA correlates with the expression of 
hlb5R estimated from the binding assay (18). Although the 
1.4-kb mRNA is specifically expressed on the cells that have 
IL-SRs and is hybridized with the probe containing only the 
coding region of kh5R.12 (data not shown), it may be too 
small to code for the 1,260-bp  ORF and UTR.  This size 
of hlb5R mRNA may code for a soluble form of hlL-5R. 
In PCR analysis, we could hardly detect the transcripts that 
correspond  to  kh5R.27  in  normal  eosinophils  (data not 
shown). 
Expression of hlLSR  in IL3-dependent Cells.  pCAGGS- 
h5R.12  was  cotransfected with  pSV2-neo  into  mlL-3- 
dependent cells, FDC-Pl, and the cells resistant to G-418 were 
selected. We picked up two clones, FDC-h5R.12 no. 2 and 
FDC-h5R.12 no. 4, expressing hlb5R by binding assay and 
checked their responsiveness to hIb5. Both clones acquired 
responsiveness to hlb5 as shown in Fig. 7. In contrast, pa- 
rental cell line  FDC-P1  or its  transfectant with pSV2-neo 
alone  (data not  shown) did not  respond to hlL-5.  It was 
confirmed that this hlL-5P, is essential to transduce signals. 
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Figure 4.  Scatchard plot analysis of 12Sl-hlL-5  or 3sS-labeled mlL-5 binding to the COS7 transfectants  expressing the cloned cDNA. The insets show 
the direct binding data (17, total binding; m, nonspecific binding). Points  are means of duplicate determinants.  (A and B) Binding of 12SI-hlb5 to 
COS7 cells transfected with pCAGGS-h5R.12 (A) or with pCAGGS-hSR.27 (B). (C and D) Binding of 3sS-labeled mlL-5 to COS7 cells transfected 
with pCAGGS-hSR.12 (C) or with pCAGGS-hSR.27 (D). 
Discussion 
In this report, we described the isolation of hlL-5R cDNA 
from human eosinophil libraries by cross-species hybridiza- 
tion using the mlL-5R ot chain cDNA that encodes IL-5 
binding protein of mlI~5R (21). The predicted mature hid 
5R has '~70% homology with that of its murine counter- 
part. It has conserved two pairs of cysteines and a "WSxWS" 
box that are the characteristics  of the cytokine receptor su- 
perfamily (22-24).  Recently, it has been reported that the 
sequence and structural pattern of the FBN III module are 
conserved in a cytokine receptor superfamily (25, 26, 43-46). 
We found not only domains with characteristics of a cytokine 
receptor superfamily, but also the NH2-terminal domain of 
IL-5R (21-125 and 18-122  amino acid residues for hlL-SR 
and mlL-SR, respectively)  has the sequence and structural 
pattern of FBN III (Fig. 2 A). The role of the FBN III module 
in this cytokine receptor superfamily is discussed in two ways. 
One possibility is that the region containing the FBN III 
module contributes to the interaction of the receptors with 
ligands or with other components of the receptor complex 
(26). In fact, mlL-SR consists of two chains, ot and/~ (47-49). 
It might simply imply that the ligand binding moiety of a 
cytokine receptor superfamily consisting of the V-shaped 
crevice between linked FBN III modules is evolved from a 
primitive adhesion molecule (25).  The other hypothesis is 
that it is involved in cell adhesion. Fukunaga et al. (43, 44) 
discussed that the similarity of the extracellular  domain of 
the G-CSF receptor with contactin may explain the role of 
this region in the communication of neutrophilic progenitor 
cells with stromal cells. Of course, these two possibilities do 
not exclude each other. These FBN III modules of a cytokine 
receptor superfamily may be involved in cell-to-cell commu- 
nication and ligand binding at the same time (45,  46). 
The cytoplasmic domain of this hlL-5R does not have any 
kinds of protein kinase domain (50),  or serine-rich  region 
observed in other cytokine receptors (39, 43-46, 51-57). How- 
ever, the proline cluster region (from Leu371 to Asp384) that 
is shared  among receptors for growth hormone (58,  59), 
prolactin (60, 61), and GM-CSF (24) is conserved as in the 
mlL-5R c~ chain (21). This fact suggests the existence of a 
certain common  interaction mechanism among these receptors. 
The existence of a second chain of hlL-SR is also suggested 
because the cytoplasmic domain of this ligand binding moiety 
346  Molecular Cloning of the Human Interleukin 5 Receptor Figure 5.  AFfinity  cross-linking. COS7 cells transfected with pCAGGS- 
hSR.12 (lanes 2, 3, 5, and 6) or a control vector pCAGGS (lanes 1 and 
4) were incubated with 5.5 nM 3sS-labeled  mlL-5 (A) or 1 nM lZSl-hlL-5 
(B) in the absence (lanes 1, 2, 4, and 5) or presence (lanes 3 and 6) of 
250-fold molar excess of unlabeled 11.-5. The cell lysates were subjected 
to SDS-PAGE  under nonreducing  conditions, and were analyzed by a Bio- 
Analyzer  100. 
Figure 6.  Detection  of hlL-5R mRNA expression in normal human 
eosinophils and other hematopoietic  cell lines. Poly(A) + RNA (6 /~g) 
from human eosinophils in peripheral blood (lane I), TF-1 (lane 2), EoL-3 
(lane 3), ATL-2  (lane 4), Raji (lane 5), and U-937 (lane 6) were subjected 
to each lane. An EcoRI fragment  of XhSR..12 was used as a probe. The 
28 S and 18 S ribosomal RNAs are indicated. 
of the hlL-5R, is too short to transduce signals.  The cyto- 
plasmic region of hlL-SR also has similarity with fl-spectrin 
as suggested (62).  It is possible that the IL-5R complex may 
be anchored in  the F-actin-containing structure. 
Analysis of rhlL-5Rs confirmed that their ligand binding 
characteristics  and their features in chemical cross-linking pat- 
terns are very similar to those of their naturally occurring 
molecules. This is quite contradictory to the constitution of 
mlL-SRs in view of the role of a second chain in the forma- 
tion of a high affinity receptor. A  functional mlL-5R con- 
sists of an ol and fl chain (47-49). While the 60-kD c~ chain 
has IL-5 binding moiety, the 130-kD fl chain does not bind 
IL-5 by itself. The ol chain itself binds IL-5 with low affinity. 
The c~/fl  heterodimer forms a high affinity mlL-5R.  The 
"~60-kD protein encoded by the cloned hlL-5R cDNA, which 
is the counterpart of the mlL-5R c~ chain, bound IIr  with 
an affinity almost similar to native hlb5R-bearing cells.  In 
terms of affinity, there are significant differences among reports 
published,  including ours. Plaetinck et al. (16) reported a single 
class  of binding  sites  with  a Ka  of 22 pM  on human eo- 
sinophilic subline from HLo60. Chihara et al.  (17) reported 
two types of hlL-SRs; one is for hypodense eosinophils with 
a Kd of 518 pM, and the other is for normodense cells with 
a Kd of 2.6 riM. Kitamura et al. (19) also reported two types 
of hlL-5R on TF-1 cells at the basal level; one is high affinity 
sites (Ka  =  120 pM), and the other is low affinity sites (Ka 
=  2 riM). On normal human eosinophils, we reported a single 
class of high affinity receptors with Kds of 170-330 pM. We 
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described that the 55-60-kD protein was cross-linked with 
35S-labeled mlL-5  (18). This protein is probably encoded by 
the  cDNA  cloned  in  this  report.  Besides  this  molecule, 
Plaetinck et al. (16) reported the 130-kD protein cross-linked 
with IL-5 on an eosinophilic subline from HL-60. Kitamura 
et al. (19) also reported 55- and 120-kD components on TF-1 
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Figure 7.  IbS-dependent proliferation  of FDC-P1 transfectants  expressing 
the hIL-5R. FDC-P1 cells were cotransfected with pCAGGS-h5R.12 and 
pSV2-neo, and two clones were isolated. [3H]Thymidine incorporations 
by FDC-P1 cells (O), FDC-h5P,.12  no. 2 clone (O), and FDC-hSR.12 
no. 4 clone (m) were determined as in Materials and Methods. Each result 
expresses the average cpm of three wells. cells. It is still not clear whether hlL-5R on normal eosinophils 
consists of two chains as in the murine  system. 
In the mI1.5R system, the B chain is proved to be I1.3R 
homologue AIC2B (48, 49), and is probably shared with GM- 
CSF receptor (GM-CSFR) (63). We can expect the hll=5R 
to also use AIC2B homologue KH97 (the/~ chain of human 
GM-CSFR.) (39, 57) for the construction of a high affinity 
receptor.  In light of these studies, our results can be inter- 
preted in two different ways concerning the contribution of 
B chain to the formation of the high affinity hI1.5R.  The 
first possibility is that the hI1.5R does not use the/~ chain 
of human GM-CSFR. It may not have a second chain as its 
constituent or may use a different protein.  However, this is 
unlikely because of the short cytoplasmic domain and con- 
served amino acid sequences of hlb5R ot chain with mouse 
homologue. The second possibility is that hI1.5R also uses 
the B chain of GM-CSFR, but it is engaged in the hlL-5R 
system in a way that  does not contribute to its affinity as 
much as in the murine system. We favor the latter possibility, 
because I1.3, I1-5,  and GM-CSF seem to work coordinately 
in hematopoiesis. Expression of human GM-CSFR in mu- 
fine FDC-P1 ceils allowed these cells to proliferate in response 
to human GM-CSF, though only low affinity receptors were 
expressed (64). Kitamura et al. (63) reported that the expres- 
sion  of the  ot chain  of human  GM-CSFR  together  with 
AIC2B (/3 chain ofmI1.5R) in CTLL-2 (IL-2-dependent mouse 
T cell line) cells conferred a growth response to human GM- 
CSF on these cells.  We observed similar phenomena in the 
case of I1.5, as shown in Fig. 7.  In this case, the hll_,5R ot 
chain probably forms a heterodimer with the B chain of mlL- 
5R like the GM-CSFR c~ chain.  We are in the process of 
checking the possibility that the B chain of human GM-CSFR 
is shared with the hlb5R by cotransfecting appropriate cells 
with cDNAs of hlL-SR and KH97 (57), the B chain of human 
GM-CSFR.. 
We detected two classes of mRNAs (•5.3  and ~1.4 kb) 
encoding hlbSR. 1.4-kb transcripts  may code for soluble form 
of hI1.5R. In addition to membrane-bound receptor forms, 
we isolated a done,  ~a5R.25,  that  encodes a soluble form 
of the hI1.5R. The soluble form has been also identified in 
the mouse (21, 62) and a common splicing mechanism seems 
to be used in two species. The biochemical characterization 
and the examination  of the expression of this molecule in 
various tissues at different stages may shed light on its bio- 
logical role. It was clear that XhSR.27-type mRNA are not 
abundant,  because this mRNA type could not be detected 
in normal eosinophils by PCR technique (data not shown). 
It is possible that the )xh5R.27-type message is restricted to 
the eosinophilia patient from whom we constructed the li- 
brary. This may imply a change in the genome or in the pro- 
cessing of the messages. 
The  expression of this  hlL-5R gene is restricted  in  eo- 
sinophils  or related cell lines as shown in this paper or in 
our previous paper (18), In the mouse, however, mlb5 selec- 
tively  supports  the  growth  of CD5 +  B  cells  besides eo- 
sinophils  in  vivo  (4).  Indeed,  Ib5R  is  expressed  in  the 
CD5 + B cell subpopulation,  and this B cell subpopulation 
is more responsive than conventional B cells are to I1.-5 (65, 
66). We have to wait before we draw any conclusions until 
an extensive survey in the detection of the hI1.5R message 
at various developmental and activated stages of human  B 
cells is done. The molecular cloning of hI1.SR cDNA also 
enabled us to study the possible role of the IL-SR in human 
disease with  an increased level  of eosinophils. 
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